Trial Outcomes & Findings for CBT+ for Depression (NCT NCT06001346)

NCT ID: NCT06001346

Last Updated: 2026-07-30

Results Overview

Working Alliance Inventory-Short Revised (WAI) is a 12-item survey on experiences over a therapy session and connection with a therapist. It consists of three subscales: tasks, goals, and therapist-client bond. The total range of scores is from 12-84 with higher scores indicating a better therapeutic alliance.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

40 participants

Primary outcome timeframe

Weeks 1-8 CBT+ visits

Results posted on

2026-07-30

Participant Flow

379 potential participants were screened online (119 excluded); 260 potential participants went on to complete a phone screen (176 excluded or declined to participate), 84 of them completed an intake assessment (44 excluded), and 40 participants were randomized as an intention to treat sample.

Participant milestones

Participant milestones
Measure
ActiveCBT
Participants will complete a standardized 30-minute exercise session on a stationary bike prior to therapy. Participants will view one of 8 standardized 30-minute nature documentary videos while exercising. ActiveCBT: Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
CalmCBT
Participants will view one of 8 standardized 30-minute nature documentary videos while resting quietly prior to therapy. CalmCBT: Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
Overall Study
STARTED
19
21
Overall Study
Analysis Population
19
21
Overall Study
COMPLETED
16
18
Overall Study
NOT COMPLETED
3
3

Reasons for withdrawal

Reasons for withdrawal
Measure
ActiveCBT
Participants will complete a standardized 30-minute exercise session on a stationary bike prior to therapy. Participants will view one of 8 standardized 30-minute nature documentary videos while exercising. ActiveCBT: Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
CalmCBT
Participants will view one of 8 standardized 30-minute nature documentary videos while resting quietly prior to therapy. CalmCBT: Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
Overall Study
Withdrawal by Subject
3
3

Baseline Characteristics

CBT+ for Depression

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
ActiveCBT
n=19 Participants
Participants will complete a standardized 30-minute exercise session on a stationary bike prior to therapy. Participants will view one of 8 standardized 30-minute nature documentary videos while exercising. ActiveCBT: Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
CalmCBT
n=21 Participants
Participants will view one of 8 standardized 30-minute nature documentary videos while resting quietly prior to therapy. CalmCBT: Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
Total
n=40 Participants
Total of all reporting groups
Age, Continuous
30.2 years
STANDARD_DEVIATION 12.8 • n=20 Participants
29.9 years
STANDARD_DEVIATION 13.3 • n=20 Participants
30.1 years
STANDARD_DEVIATION 12.9 • n=40 Participants
Sex/Gender, Customized
Male
6 Participants
n=20 Participants
8 Participants
n=20 Participants
14 Participants
n=40 Participants
Sex/Gender, Customized
Female
13 Participants
n=20 Participants
12 Participants
n=20 Participants
25 Participants
n=40 Participants
Sex/Gender, Customized
Gender nonconforming
0 Participants
n=20 Participants
1 Participants
n=20 Participants
1 Participants
n=40 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
n=20 Participants
4 Participants
n=20 Participants
6 Participants
n=40 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
17 Participants
n=20 Participants
16 Participants
n=20 Participants
33 Participants
n=40 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=20 Participants
1 Participants
n=20 Participants
1 Participants
n=40 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
Race (NIH/OMB)
Asian
1 Participants
n=20 Participants
0 Participants
n=20 Participants
1 Participants
n=40 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
Race (NIH/OMB)
White
17 Participants
n=20 Participants
16 Participants
n=20 Participants
33 Participants
n=40 Participants
Race (NIH/OMB)
More than one race
1 Participants
n=20 Participants
5 Participants
n=20 Participants
6 Participants
n=40 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
Region of Enrollment
United States
19 participants
n=20 Participants
21 participants
n=20 Participants
40 participants
n=40 Participants
Education
High School Graduate
1 Participants
n=20 Participants
1 Participants
n=20 Participants
2 Participants
n=40 Participants
Education
Some College
8 Participants
n=20 Participants
11 Participants
n=20 Participants
19 Participants
n=40 Participants
Education
College Graduate
3 Participants
n=20 Participants
5 Participants
n=20 Participants
8 Participants
n=40 Participants
Education
Some Postgraduate School
3 Participants
n=20 Participants
2 Participants
n=20 Participants
5 Participants
n=40 Participants
Education
Graduate Degree
4 Participants
n=20 Participants
2 Participants
n=20 Participants
6 Participants
n=40 Participants
Employment
Other
0 Participants
n=20 Participants
2 Participants
n=20 Participants
2 Participants
n=40 Participants
Employment
Part Time
6 Participants
n=20 Participants
9 Participants
n=20 Participants
15 Participants
n=40 Participants
Employment
Full Time
9 Participants
n=20 Participants
7 Participants
n=20 Participants
16 Participants
n=40 Participants
Employment
Student
4 Participants
n=20 Participants
3 Participants
n=20 Participants
7 Participants
n=40 Participants
Income
Less than $25,000
5 Participants
n=20 Participants
8 Participants
n=20 Participants
13 Participants
n=40 Participants
Income
$25,000-$49,999
1 Participants
n=20 Participants
5 Participants
n=20 Participants
6 Participants
n=40 Participants
Income
$50,000-$74,999
1 Participants
n=20 Participants
2 Participants
n=20 Participants
3 Participants
n=40 Participants
Income
$75,000-$99,999
4 Participants
n=20 Participants
2 Participants
n=20 Participants
6 Participants
n=40 Participants
Income
$100,000 or more
8 Participants
n=20 Participants
4 Participants
n=20 Participants
12 Participants
n=40 Participants
Marital Status
Married / Partnered
9 Participants
n=20 Participants
8 Participants
n=20 Participants
17 Participants
n=40 Participants
Marital Status
Single / Separated / Divorced
10 Participants
n=20 Participants
13 Participants
n=20 Participants
23 Participants
n=40 Participants
Currently in Therapy
8 Participants
n=20 Participants
5 Participants
n=20 Participants
13 Participants
n=40 Participants
Using Any Mental Health Medication
8 Participants
n=20 Participants
8 Participants
n=20 Participants
16 Participants
n=40 Participants

PRIMARY outcome

Timeframe: Weeks 1-8 CBT+ visits

Population: Missing data represents participants that withdrew from the study or did not provide data at subsequent time points.

Working Alliance Inventory-Short Revised (WAI) is a 12-item survey on experiences over a therapy session and connection with a therapist. It consists of three subscales: tasks, goals, and therapist-client bond. The total range of scores is from 12-84 with higher scores indicating a better therapeutic alliance.

Outcome measures

Outcome measures
Measure
ActiveCBT
n=19 Participants
Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
CalmCBT
n=21 Participants
Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
Average Self-reported Working Alliance Measured by Working Alliance Inventory (WAI)
Week 2
47.8 score on a scale
Standard Deviation 5.99
45.8 score on a scale
Standard Deviation 9.02
Average Self-reported Working Alliance Measured by Working Alliance Inventory (WAI)
Week 3
49.9 score on a scale
Standard Deviation 6.05
48.1 score on a scale
Standard Deviation 9.24
Average Self-reported Working Alliance Measured by Working Alliance Inventory (WAI)
Week 1
42.2 score on a scale
Standard Deviation 6.43
42.8 score on a scale
Standard Deviation 8.89
Average Self-reported Working Alliance Measured by Working Alliance Inventory (WAI)
Week 4
51.1 score on a scale
Standard Deviation 6.27
49.6 score on a scale
Standard Deviation 10.4
Average Self-reported Working Alliance Measured by Working Alliance Inventory (WAI)
Week 5
53.2 score on a scale
Standard Deviation 4.92
51.2 score on a scale
Standard Deviation 7.63
Average Self-reported Working Alliance Measured by Working Alliance Inventory (WAI)
Week 6
52.0 score on a scale
Standard Deviation 7.79
51.7 score on a scale
Standard Deviation 7.60
Average Self-reported Working Alliance Measured by Working Alliance Inventory (WAI)
Week 7
53.7 score on a scale
Standard Deviation 6.69
53.6 score on a scale
Standard Deviation 7.16
Average Self-reported Working Alliance Measured by Working Alliance Inventory (WAI)
Week 8
55.7 score on a scale
Standard Deviation 4.33
55.0 score on a scale
Standard Deviation 5.26

PRIMARY outcome

Timeframe: Intake, Weeks 1-8 CBT+ visits, Week 9 (Post-therapy), 12-week follow up, 1-year follow-up

Population: Missing data represents participants that withdrew from the study or did not provide data at subsequent time points.

The Behavioral Activation for Depression Scale (BADS) will be used to assess changes in behavioral activity. The scale is designed to be administered weekly to measure changes over the course of Behavioral Activation for depression. It consists of 25 questions that inquire about Activation, Avoidance/Rumination, Work/School Impairment, and Social Impairment. Each item is rated on a 7-point scale from 0 (Not at all) to 6 (Completely) with total scores ranging: 0-150 where higher scores indicate greater behavioral activation.

Outcome measures

Outcome measures
Measure
ActiveCBT
n=19 Participants
Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
CalmCBT
n=21 Participants
Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
Self-reported Behavioral Activation Measured by Behavioral Activation for Depression Scale (BADS)
Intake
72.7 score on a scale
Standard Deviation 17.2
69.1 score on a scale
Standard Deviation 24.2
Self-reported Behavioral Activation Measured by Behavioral Activation for Depression Scale (BADS)
Weeks 1
72.7 score on a scale
Standard Deviation 19.3
70.3 score on a scale
Standard Deviation 22.9
Self-reported Behavioral Activation Measured by Behavioral Activation for Depression Scale (BADS)
Week 2
79.1 score on a scale
Standard Deviation 19.2
69.6 score on a scale
Standard Deviation 22.7
Self-reported Behavioral Activation Measured by Behavioral Activation for Depression Scale (BADS)
Week 3
84.4 score on a scale
Standard Deviation 22.3
81.1 score on a scale
Standard Deviation 21.1
Self-reported Behavioral Activation Measured by Behavioral Activation for Depression Scale (BADS)
Week 4
87.1 score on a scale
Standard Deviation 18.9
77.9 score on a scale
Standard Deviation 17.8
Self-reported Behavioral Activation Measured by Behavioral Activation for Depression Scale (BADS)
Week 5
88.4 score on a scale
Standard Deviation 25.2
85.4 score on a scale
Standard Deviation 13.1
Self-reported Behavioral Activation Measured by Behavioral Activation for Depression Scale (BADS)
Week 6
94.0 score on a scale
Standard Deviation 21.4
82.9 score on a scale
Standard Deviation 13.1
Self-reported Behavioral Activation Measured by Behavioral Activation for Depression Scale (BADS)
Week 7
95.8 score on a scale
Standard Deviation 23.4
92.1 score on a scale
Standard Deviation 22.3
Self-reported Behavioral Activation Measured by Behavioral Activation for Depression Scale (BADS)
Week 8
101 score on a scale
Standard Deviation 23.9
93.3 score on a scale
Standard Deviation 25.3
Self-reported Behavioral Activation Measured by Behavioral Activation for Depression Scale (BADS)
Week 9 (Post-therapy)
106 score on a scale
Standard Deviation 20.7
98.2 score on a scale
Standard Deviation 25.3
Self-reported Behavioral Activation Measured by Behavioral Activation for Depression Scale (BADS)
12 week follow up
103 score on a scale
Standard Deviation 20.6
101 score on a scale
Standard Deviation 22.2
Self-reported Behavioral Activation Measured by Behavioral Activation for Depression Scale (BADS)
1 year follow up
108 score on a scale
Standard Deviation 21.3
96.4 score on a scale
Standard Deviation 22.4

SECONDARY outcome

Timeframe: Intake, Week 9 (Post-therapy), 12-week follow up, 1-year follow up

Population: Missing data represents participants that withdrew from the study or did not provide data at subsequent time points.

The GRID-HAM-D is a clinician-completed questionnaire that will be used to rate depressive symptom severity. The questionnaire is designed for adults and is used to rate the intensity and frequency of depressive symptoms by probing mood, feelings of guilt, suicidal ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. As recommended by the Depression Rating Scale Standardization Team, Clinical Interviewers will follow the Structured Interview Guide and use GRID scoring, in which dimensions of intensity and frequency of a symptom are rated independently for each item. Total scores are calculated from each question and range from 0 to 52, with higher scores indicated greater depressive symptom severity.

Outcome measures

Outcome measures
Measure
ActiveCBT
n=19 Participants
Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
CalmCBT
n=21 Participants
Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
Change in Clinician-rated Depression Symptoms Measured by GRID-Hamilton Depression Rating Scale (GRID-HAM-D) From Intake
Intake to Week 9 (Post-therapy)
-7.38 score on a scale
Standard Deviation 6.99
-6.72 score on a scale
Standard Deviation 4.87
Change in Clinician-rated Depression Symptoms Measured by GRID-Hamilton Depression Rating Scale (GRID-HAM-D) From Intake
Intake to 12 week follow up
-8.00 score on a scale
Standard Deviation 7.30
-7.06 score on a scale
Standard Deviation 4.90
Change in Clinician-rated Depression Symptoms Measured by GRID-Hamilton Depression Rating Scale (GRID-HAM-D) From Intake
Intake to 1 year follow up
-9.18 score on a scale
Standard Deviation 7.24
-8.44 score on a scale
Standard Deviation 6.10

SECONDARY outcome

Timeframe: Weeks 1-8 CBT+ visits, Week 9 (Post-therapy), 12-week follow up, 1-year follow-up

Population: Missing data represents participants that withdrew from the study or did not provide data at subsequent time points.

The Patient Health Questionnaire-9 (PHQ-9) is a 9-question self-report instrument used to assess presence and severity of depressive symptoms, with scores categorized 0-4, 5-9, 10-14, 15-19, and 20-27 as minimal, mild, moderate, moderately severe, and severe depression, respectively.

Outcome measures

Outcome measures
Measure
ActiveCBT
n=19 Participants
Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
CalmCBT
n=21 Participants
Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
Change in Self-reported Depression Symptoms Measured by Patient Health Questionnaire-9 (PHQ-9) From Week 1
Week 1 to Week 2
-0.500 score on a scale
Standard Deviation 3.07
-1.20 score on a scale
Standard Deviation 2.78
Change in Self-reported Depression Symptoms Measured by Patient Health Questionnaire-9 (PHQ-9) From Week 1
Week 1 to Week 3
-2.24 score on a scale
Standard Deviation 3.19
-3.21 score on a scale
Standard Deviation 5.40
Change in Self-reported Depression Symptoms Measured by Patient Health Questionnaire-9 (PHQ-9) From Week 1
Week 1 to Week 4
-1.94 score on a scale
Standard Deviation 3.91
-2.33 score on a scale
Standard Deviation 4.37
Change in Self-reported Depression Symptoms Measured by Patient Health Questionnaire-9 (PHQ-9) From Week 1
Week 1 to Week 5
-2.63 score on a scale
Standard Deviation 4.26
-3.89 score on a scale
Standard Deviation 4.61
Change in Self-reported Depression Symptoms Measured by Patient Health Questionnaire-9 (PHQ-9) From Week 1
Week 1 to Week 6
-3.27 score on a scale
Standard Deviation 4.10
-4.50 score on a scale
Standard Deviation 4.41
Change in Self-reported Depression Symptoms Measured by Patient Health Questionnaire-9 (PHQ-9) From Week 1
Week 1 to Week 7
-3.13 score on a scale
Standard Deviation 4.70
-5.50 score on a scale
Standard Deviation 5.66
Change in Self-reported Depression Symptoms Measured by Patient Health Questionnaire-9 (PHQ-9) From Week 1
Week 1 to Week 8
-4.80 score on a scale
Standard Deviation 3.78
-6.44 score on a scale
Standard Deviation 5.93
Change in Self-reported Depression Symptoms Measured by Patient Health Questionnaire-9 (PHQ-9) From Week 1
Week 1 to Week 9 (Post-Therapy)
-5.13 score on a scale
Standard Deviation 4.42
-6.39 score on a scale
Standard Deviation 6.64
Change in Self-reported Depression Symptoms Measured by Patient Health Questionnaire-9 (PHQ-9) From Week 1
Week 1 to 12 week follow up
-6.14 score on a scale
Standard Deviation 4.55
-7.72 score on a scale
Standard Deviation 5.64
Change in Self-reported Depression Symptoms Measured by Patient Health Questionnaire-9 (PHQ-9) From Week 1
Week 1 to 1 year follow up
-6.73 score on a scale
Standard Deviation 5.46
-6.88 score on a scale
Standard Deviation 6.15

SECONDARY outcome

Timeframe: Intake, Week 9 (Post-therapy), 12-week follow up, 1-year follow up

Population: Missing data represents participants that withdrew from the study or did not provide data at subsequent time points.

The SCID is a clinician-administered semi-structured interview guide for making diagnoses according to the diagnostic criteria published in the American Psychiatric Association's Diagnostic and Statistical Manual for Mental Disorders (DSM-5). It provides diagnoses for inclusion and exclusionary diagnoses. Results show number of participants who meet criteria for Major Depressive Disorder (i.e., 'checked') or no longer meet criteria (i.e., 'unchecked').

Outcome measures

Outcome measures
Measure
ActiveCBT
n=19 Participants
Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
CalmCBT
n=21 Participants
Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
MDD Diagnosis Measured by Structured Clinical Interview for DSM-5 Disorders (SCID)
Intake · Checked
19 Participants
21 Participants
MDD Diagnosis Measured by Structured Clinical Interview for DSM-5 Disorders (SCID)
Intake · Unchecked
0 Participants
0 Participants
MDD Diagnosis Measured by Structured Clinical Interview for DSM-5 Disorders (SCID)
Week 9 (Post-therapy) · Checked
2 Participants
2 Participants
MDD Diagnosis Measured by Structured Clinical Interview for DSM-5 Disorders (SCID)
Week 9 (Post-therapy) · Unchecked
14 Participants
16 Participants
MDD Diagnosis Measured by Structured Clinical Interview for DSM-5 Disorders (SCID)
12 week follow up · Checked
1 Participants
1 Participants
MDD Diagnosis Measured by Structured Clinical Interview for DSM-5 Disorders (SCID)
12 week follow up · Unchecked
13 Participants
17 Participants
MDD Diagnosis Measured by Structured Clinical Interview for DSM-5 Disorders (SCID)
1 year follow up · Checked
1 Participants
3 Participants
MDD Diagnosis Measured by Structured Clinical Interview for DSM-5 Disorders (SCID)
1 year follow up · Unchecked
10 Participants
13 Participants

SECONDARY outcome

Timeframe: Weeks 1-8 CBT+ visits (repeated 3 times [before exercise/calm condition, immediately after exercise/calm condition, and after therapy])

Population: Missing data represents participants that withdrew from the study or did not provide data at subsequent time points.

The DARS is a self-report measure that assesses state anhedonia across multiple domains. DARS is a 17-item survey on state anhedonia divided into four domains: hobbies, food/drink, social activities, and sensory experiences. Subjects must list two activities within each of these categories that they consider their favorite and then respond to questions regarding their interest in/enjoyment of those activities on a 5-point Likert scale from "Not at all" (0) to "Very much" (4), with total scores ranging from 0 to 68, with higher scores representing reduced anhedonia.

Outcome measures

Outcome measures
Measure
ActiveCBT
n=19 Participants
Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
CalmCBT
n=21 Participants
Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
pre Week 1
39.4 score on a scale
Standard Deviation 12.2
34.8 score on a scale
Standard Deviation 15.4
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
mid Week 1
42.3 score on a scale
Standard Deviation 11.6
36.0 score on a scale
Standard Deviation 16.8
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
post Week 1
40.1 score on a scale
Standard Deviation 15.2
39.9 score on a scale
Standard Deviation 17.3
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
pre Week 2
39.1 score on a scale
Standard Deviation 11.8
37.1 score on a scale
Standard Deviation 13.5
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
mid Week 2
43.3 score on a scale
Standard Deviation 10.4
36.1 score on a scale
Standard Deviation 15.4
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
post Week 2
45.6 score on a scale
Standard Deviation 10.4
42.6 score on a scale
Standard Deviation 13.4
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
pre Week 3
37.9 score on a scale
Standard Deviation 12.1
34.9 score on a scale
Standard Deviation 15.0
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
mid Week 3
41.4 score on a scale
Standard Deviation 11.2
38.9 score on a scale
Standard Deviation 17.0
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
post Week 3
44.4 score on a scale
Standard Deviation 8.30
42.2 score on a scale
Standard Deviation 18.7
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
pre Week 4
39.3 score on a scale
Standard Deviation 13.7
36.1 score on a scale
Standard Deviation 17.7
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
mid Week 4
44.8 score on a scale
Standard Deviation 12.5
39.8 score on a scale
Standard Deviation 18.1
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
post Week 4
47.2 score on a scale
Standard Deviation 13.6
44.2 score on a scale
Standard Deviation 18.5
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
pre Week 5
38.1 score on a scale
Standard Deviation 13.9
39.2 score on a scale
Standard Deviation 16.6
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
mid Week 5
41.3 score on a scale
Standard Deviation 15.2
39.9 score on a scale
Standard Deviation 20.7
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
post Week 5
47.6 score on a scale
Standard Deviation 13.3
46.5 score on a scale
Standard Deviation 17.3
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
pre Week 6
37.7 score on a scale
Standard Deviation 12.1
33.7 score on a scale
Standard Deviation 16.3
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
mid Week 6
41.7 score on a scale
Standard Deviation 14.5
37.1 score on a scale
Standard Deviation 16.5
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
post Week 6
44.5 score on a scale
Standard Deviation 12.7
42.0 score on a scale
Standard Deviation 18.0
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
pre Week 7
34.7 score on a scale
Standard Deviation 14.8
43.1 score on a scale
Standard Deviation 17.8
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
mid Week 7
38.6 score on a scale
Standard Deviation 14.9
41.9 score on a scale
Standard Deviation 18.5
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
post Week 7
44.3 score on a scale
Standard Deviation 9.45
44.4 score on a scale
Standard Deviation 18.3
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
pre Week 8
42.1 score on a scale
Standard Deviation 9.45
40.2 score on a scale
Standard Deviation 19.7
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
mid Week 8
47.6 score on a scale
Standard Deviation 10.3
42.6 score on a scale
Standard Deviation 19.0
Average Anhedonia Measured by Dimensional Anhedonia Rating Scale (DARS)
post Week 8
51.3 score on a scale
Standard Deviation 11.0
46.1 score on a scale
Standard Deviation 18.4

SECONDARY outcome

Timeframe: Weeks 1-8 CBT+ visits (repeated 3 times [before exercise/calm condition, immediately after exercise/calm condition, and after therapy])

Population: Missing data represents participants that withdrew from the study or did not provide data at subsequent time points.

An anhedonia Visual Analog Scale \[VAS\] with 0 indicating 'No pleasure at all' and 100 indicating 'Greatest pleasure imaginable' will be used to measure anhedonia. The VAS will be used to provide a supplementary assessment of anhedonia.

Outcome measures

Outcome measures
Measure
ActiveCBT
n=19 Participants
Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
CalmCBT
n=21 Participants
Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
mid Week 2
53.9 score on a scale
Standard Deviation 12.8
47.2 score on a scale
Standard Deviation 11.8
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
pre Week 1
38.2 score on a scale
Standard Deviation 17.9
38.8 score on a scale
Standard Deviation 20.7
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
mid Week 1
54.5 score on a scale
Standard Deviation 13.4
46.0 score on a scale
Standard Deviation 16.1
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
post Week 1
57.8 score on a scale
Standard Deviation 13.2
57.3 score on a scale
Standard Deviation 18.0
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
pre Week 2
44.7 score on a scale
Standard Deviation 17.0
42.9 score on a scale
Standard Deviation 15.3
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
post Week 2
56.1 score on a scale
Standard Deviation 14.7
61.5 score on a scale
Standard Deviation 13.2
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
pre Week 3
46.0 score on a scale
Standard Deviation 13.3
44.9 score on a scale
Standard Deviation 16.0
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
mid Week 3
53.6 score on a scale
Standard Deviation 8.96
53.3 score on a scale
Standard Deviation 11.4
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
post Week 3
63.0 score on a scale
Standard Deviation 9.24
59.4 score on a scale
Standard Deviation 13.6
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
pre Week 4
46.8 score on a scale
Standard Deviation 13.8
42.1 score on a scale
Standard Deviation 14.3
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
mid Week 4
56.2 score on a scale
Standard Deviation 8.66
53.7 score on a scale
Standard Deviation 10.0
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
post Week 4
64.3 score on a scale
Standard Deviation 11.6
65.3 score on a scale
Standard Deviation 17.0
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
pre Week 5
42.4 score on a scale
Standard Deviation 16.7
48.4 score on a scale
Standard Deviation 13.8
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
mid Week 5
56.9 score on a scale
Standard Deviation 7.96
54.2 score on a scale
Standard Deviation 10.5
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
post Week 5
66.1 score on a scale
Standard Deviation 9.84
66.5 score on a scale
Standard Deviation 14.8
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
pre Week 6
48.5 score on a scale
Standard Deviation 9.13
41.3 score on a scale
Standard Deviation 14.8
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
mid Week 6
56.8 score on a scale
Standard Deviation 7.59
45.5 score on a scale
Standard Deviation 15.8
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
post Week 6
65.7 score on a scale
Standard Deviation 13.1
60.6 score on a scale
Standard Deviation 15.4
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
pre Week 7
48.0 score on a scale
Standard Deviation 17.0
54.6 score on a scale
Standard Deviation 15.8
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
mid Week 7
54.2 score on a scale
Standard Deviation 12.0
61.0 score on a scale
Standard Deviation 12.8
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
post Week 7
65.6 score on a scale
Standard Deviation 11.9
65.2 score on a scale
Standard Deviation 22.2
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
pre Week 8
56.1 score on a scale
Standard Deviation 9.78
54.1 score on a scale
Standard Deviation 15.5
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
mid Week 8
62.1 score on a scale
Standard Deviation 9.77
59.2 score on a scale
Standard Deviation 8.93
Average Anhedonia Measured by an Anhedonia Visual Analogue Scale (Anhedonia VAS)
post Week 8
70.7 score on a scale
Standard Deviation 12.3
68.9 score on a scale
Standard Deviation 15.5

SECONDARY outcome

Timeframe: Weeks 1, 4, and 8 CBT+ visits (before exercise/calm condition, immediately after exercise/calm condition, and after therapy)

Population: Missing data represents participants that withdrew from the study or did not provide data at subsequent time points. Investigators were unable to obtain blood samples from all participants (e.g., participant declined blood draw, phlebotomist unable to collect samples).

Serum BDNF will be quantified from a standard blood draw. Blood samples collected during Visits 1, 4, and 8 will be allowed to clot for 30 minutes and then centrifuged for ten minutes at 5500 RPM and 4 ◦C. Following centrifugation, blood serum will be extracted with samples stored at -80 ◦C until BDNF analysis. Enzyme-linked immunosorbent assay (ELISA) kits will measure the concentration of total BDNF in the serum according to the manufacturer's instructions. Each blood sample will be run in duplicate and averaged.

Outcome measures

Outcome measures
Measure
ActiveCBT
n=19 Participants
Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
CalmCBT
n=21 Participants
Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
Serum Brain Derived Neurotrophic Factor (BDNF)
pre Week 1
230 ng/mL
Standard Deviation 68.4
220 ng/mL
Standard Deviation 76.6
Serum Brain Derived Neurotrophic Factor (BDNF)
mid Week 1
315 ng/mL
Standard Deviation 114
228 ng/mL
Standard Deviation 90.9
Serum Brain Derived Neurotrophic Factor (BDNF)
post Week 1
262 ng/mL
Standard Deviation 95.2
240 ng/mL
Standard Deviation 107
Serum Brain Derived Neurotrophic Factor (BDNF)
pre Week 4
307 ng/mL
Standard Deviation 131
237 ng/mL
Standard Deviation 101
Serum Brain Derived Neurotrophic Factor (BDNF)
mid Week 4
293 ng/mL
Standard Deviation 168
202 ng/mL
Standard Deviation 91.1
Serum Brain Derived Neurotrophic Factor (BDNF)
post Week 4
293 ng/mL
Standard Deviation 133
205 ng/mL
Standard Deviation 61.7
Serum Brain Derived Neurotrophic Factor (BDNF)
pre Week 8
255 ng/mL
Standard Deviation 83.9
196 ng/mL
Standard Deviation 80.7
Serum Brain Derived Neurotrophic Factor (BDNF)
mid Week 8
256 ng/mL
Standard Deviation 77.7
199 ng/mL
Standard Deviation 86.1
Serum Brain Derived Neurotrophic Factor (BDNF)
post Week 8
240 ng/mL
Standard Deviation 89.8
226 ng/mL
Standard Deviation 107

SECONDARY outcome

Timeframe: Intake, week 4 CBT+ visit, Week 9 (Post-therapy), 12-week follow up, 1-year follow up

Population: Missing data represents participants that withdrew from the study or did not provide data at subsequent time points.

Generalized Anxiety Disorder 7 (GAD-7) is a self-reported questionnaire for measuring generalized anxiety disorder. GAD-7 has seven items, which measure the severity of various signs of GAD according to reported response categories of: Not at all (0 points), Several days (1 point), More than half the days (2 points), and Nearly every day (3 points). A total score is calculated ranging from 0 to 21, with higher scores indicating more severe anxiety symptoms.

Outcome measures

Outcome measures
Measure
ActiveCBT
n=19 Participants
Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
CalmCBT
n=21 Participants
Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
Change in Anxiety Measured by Generalized Anxiety Disorder 7 (GAD-7) From Intake
Intake to Week 4
-1.00 score on a scale
Standard Deviation 3.69
-0.389 score on a scale
Standard Deviation 3.09
Change in Anxiety Measured by Generalized Anxiety Disorder 7 (GAD-7) From Intake
Intake to Week 9 (Post-Therapy)
-4.50 score on a scale
Standard Deviation 5.37
-3.94 score on a scale
Standard Deviation 5.10
Change in Anxiety Measured by Generalized Anxiety Disorder 7 (GAD-7) From Intake
Intake to 12 week follow up
-4.57 score on a scale
Standard Deviation 5.30
-4.89 score on a scale
Standard Deviation 5.23
Change in Anxiety Measured by Generalized Anxiety Disorder 7 (GAD-7) From Intake
Intake to 1 year follow up
-4.91 score on a scale
Standard Deviation 4.74
-3.47 score on a scale
Standard Deviation 6.64

SECONDARY outcome

Timeframe: Intake, weeks 1-8 CBT+ visits, Week 9 (Post-therapy), 12-week follow up, 1-year follow-up

Population: Missing data represents participants that withdrew from the study or did not provide data at subsequent time points.

The ATQ is a 30-item instrument that measures the frequency of automatic negative statements about the self. Each item is rated on the frequency of an occurrence from "not at all" to "all the time". Total scores are the sum of all 30 items (ranging 30-150), with higher totals indicating a higher level of automatic negative self-statements.

Outcome measures

Outcome measures
Measure
ActiveCBT
n=19 Participants
Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
CalmCBT
n=21 Participants
Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
Average Automatic Thoughts Measured by Automatic Thoughts Questionnaire (ATQ)
Week 2
76.5 score on a scale
Standard Deviation 26.9
91.0 score on a scale
Standard Deviation 22.1
Average Automatic Thoughts Measured by Automatic Thoughts Questionnaire (ATQ)
Intake
85.6 score on a scale
Standard Deviation 26.5
95.8 score on a scale
Standard Deviation 23.4
Average Automatic Thoughts Measured by Automatic Thoughts Questionnaire (ATQ)
Week 1
82.3 score on a scale
Standard Deviation 26.5
91.0 score on a scale
Standard Deviation 27.3
Average Automatic Thoughts Measured by Automatic Thoughts Questionnaire (ATQ)
Week 3
77.6 score on a scale
Standard Deviation 29.4
82.9 score on a scale
Standard Deviation 24.6
Average Automatic Thoughts Measured by Automatic Thoughts Questionnaire (ATQ)
Week 4
74.1 score on a scale
Standard Deviation 25.2
83.1 score on a scale
Standard Deviation 22.8
Average Automatic Thoughts Measured by Automatic Thoughts Questionnaire (ATQ)
Week 5
67.3 score on a scale
Standard Deviation 26.1
75.8 score on a scale
Standard Deviation 24.1
Average Automatic Thoughts Measured by Automatic Thoughts Questionnaire (ATQ)
Week 6
63.9 score on a scale
Standard Deviation 25.1
76.3 score on a scale
Standard Deviation 28.5
Average Automatic Thoughts Measured by Automatic Thoughts Questionnaire (ATQ)
Week 7
63.0 score on a scale
Standard Deviation 25.1
67.5 score on a scale
Standard Deviation 26.5
Average Automatic Thoughts Measured by Automatic Thoughts Questionnaire (ATQ)
Week 8
55.7 score on a scale
Standard Deviation 21.7
67.1 score on a scale
Standard Deviation 27.2
Average Automatic Thoughts Measured by Automatic Thoughts Questionnaire (ATQ)
Week 9 (Post Therapy)
50.9 score on a scale
Standard Deviation 20.2
63.6 score on a scale
Standard Deviation 27.6
Average Automatic Thoughts Measured by Automatic Thoughts Questionnaire (ATQ)
12 week follow up
51.1 score on a scale
Standard Deviation 20.1
55.1 score on a scale
Standard Deviation 21.9
Average Automatic Thoughts Measured by Automatic Thoughts Questionnaire (ATQ)
1 year follow up
57.5 score on a scale
Standard Deviation 28.2
54.2 score on a scale
Standard Deviation 19.8

SECONDARY outcome

Timeframe: Weeks 1-8 CBT+ visits

Population: Missing data represents participants that withdrew from the study or did not provide data at subsequent time points.

Session Evaluation Questionnaire (SEQ) will be used to evaluate session effectiveness. This includes responses to twenty-one items in a 7-point bipolar adjective format questionnaire to assess how the client feels about each CBT session. The questionnaire assesses session depth, smoothness, positivity, and arousal. An overall score of the subscales will be used in this study (ranging 7-28). Higher scores indicate more favorable session evaluations.

Outcome measures

Outcome measures
Measure
ActiveCBT
n=19 Participants
Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
CalmCBT
n=21 Participants
Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
Average Session Effectiveness Measured by Session Evaluation Questionnaire (SEQ)
Week 1
18.1 score on a scale
Standard Deviation 1.76
17.7 score on a scale
Standard Deviation 2.86
Average Session Effectiveness Measured by Session Evaluation Questionnaire (SEQ)
Week 2
18.7 score on a scale
Standard Deviation 2.63
19.0 score on a scale
Standard Deviation 3.15
Average Session Effectiveness Measured by Session Evaluation Questionnaire (SEQ)
Week 3
19.1 score on a scale
Standard Deviation 2.21
19.0 score on a scale
Standard Deviation 3.63
Average Session Effectiveness Measured by Session Evaluation Questionnaire (SEQ)
Week 4
19.5 score on a scale
Standard Deviation 2.90
19.7 score on a scale
Standard Deviation 3.28
Average Session Effectiveness Measured by Session Evaluation Questionnaire (SEQ)
Week 5
20.3 score on a scale
Standard Deviation 2.27
19.5 score on a scale
Standard Deviation 3.68
Average Session Effectiveness Measured by Session Evaluation Questionnaire (SEQ)
Week 6
20.2 score on a scale
Standard Deviation 3.31
19.4 score on a scale
Standard Deviation 3.24
Average Session Effectiveness Measured by Session Evaluation Questionnaire (SEQ)
Week 7
19.6 score on a scale
Standard Deviation 2.94
19.9 score on a scale
Standard Deviation 4.02
Average Session Effectiveness Measured by Session Evaluation Questionnaire (SEQ)
Week 8
21.6 score on a scale
Standard Deviation 2.13
21.0 score on a scale
Standard Deviation 3.17

OTHER_PRE_SPECIFIED outcome

Timeframe: Weeks 1-8 CBT+ visits

Lyssn is an AI-powered assessment platform for recording and managing session files, and all clinical interviews and therapy sessions will be recorded on the Lyssn platform. Lyssn will process the audio files from therapy sessions to generate session-level data regarding collaboration and empathy as metrics related to the primary client ratings of working alliance, as well as generating CTRS fidelity metrics which will be used in the ongoing supervision and fidelity monitoring of all sessions.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Intake, Weeks 1, 4, and 8 CBT+ visits (before exercise/calm condition, immediately after exercise/calm condition, and after therapy)

The NCI consist of 6 questions pertaining to nature connectedness. Participants respond using a 7-point Likert scale, ranging from 1 (Strongly Disagree) to 7 (Strongly Agree), with higher scores indicating greater levels of nature connectedness.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Intake, weeks 4 & 8 CBT+ visits (monitors worn 1 week following each time point)

Participants will place an activPAL on the midline of the thigh on either leg and wear the monitor during all waking hours, removing it only for water-based activities (e.g., swimming). For data to be valid, the monitor must have been worn for 20 hours on at least 4 days, including a minimum of 3 weekdays and 1 weekend day. Sleep time will be parsed out from each day's sitting/lying time automatically using PALanalysis. From these data, average minutes of sitting per day will be used to assess total sedentary time, minutes of stepping time with a cadence ≥75 and \<100 will be used to assess minutes of light-intensity physical activity and minutes of stepping time with a cadence ≥100 will be used to assess minutes of moderate to vigorous physical activity (MVPA).

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Intake, week 4 CBT+ visit, Week 9 (Post-therapy), 12-week follow up, 1-year follow up

The SF-36 assesses health-related quality of life. It consists of eight scaled scores (including vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health), which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The higher the score the less disability (i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability).

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Intake, week 4 CBT+ visit, Week 9 (Post-therapy), 12-week follow up, 1-year follow up

The IPAQ is a physical activity questionnaire that inquires about average amounts of walking, moderate physical activity, vigorous physical activity, and sitting time per week.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Intake, weeks 1-8 CBT+ visits, Week 9 (Post-therapy), 12-week follow up, 1-year follow-up

The C-SSRS will be used to assess and monitor suicide ideation and behavior. The severity of the ideation subscale is rated on a 5-point ordinal scale: 1 = wish to be dead, 2 = nonspecific active suicidal thoughts, 3 = suicidal thoughts with methods, 4 =suicidal intent, and 5 = suicidal intent with plan. Suicide behaviors are rated on a nominal scale that includes actual, aborted, and interrupted attempts; preparatory behavior; and non-suicidal,self-injurious behavior.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Intake

Health history will be self-reported. In addition, participants will be asked to list their current medications.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Intake

Demographic characteristics including age, sex, race, education, marital status, occupational status, and household income will be recorded or measured to characterize the sample.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Intake

The ACES consists of 16 questions pertaining to the respondents' first 18 years of life. Participants respond with yes or no regarding if a childhood adverse event occurred. Adverse events questions are grouped by categories. Participants are scored for each event category they are exposed to with scores ranging from 0 (unexposed) to 7 (exposed to all categories).

Outcome measures

Outcome data not reported

Adverse Events

ActiveCBT

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

CalmCBT

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jacob Meyer

University of Wisconsin - Madison

Phone: (608) 890-3239

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place